Deuterium depletion inhibits lung cancer cell growth and migration in vitro and results in severalfold increase of median survival time of non-small cell lung cancer patients receiving conventional therapy
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for 84% of all lung cancer diagnoses. In advanced
NSCLC, including adenocarcinoma and squamous cell carcinoma, median survival time (MST) rarely exceeds 10-12 months. Reduced
deuterium (D) concentration in water of tissue culture media and in drinking water for humans has shown a strong anticancer effect in
previous investigations. In the present study, 1 parts per million (ppm) decrease of D-concentration every 8 hours resulted in reduced
growth rate of the A459 lung cancer cell line in vitro, and the cell migration was also dose-dependently reduced. Retrospective study
of 183 NSCLC patients consuming commercially available deuterium-depleted water (DDW) revealed a severalfold increase of MST,
which was 149 months for 19 patients and 40 months for 110 patients, who started DDW-consumption at early or advanced stage,
respectively. Interestingly, MST showed a significant difference by gender (107 months in females and 41.2 months in males). Application
of DDW in combination with surgery plus other conventional therapies (68 patients) gave 149 months MST, while for DDW combined
with chemotherapy only (48 patients) MST was 43.7 months. The present results support earlier data that integration of D-depletion to
conventional therapies increases the efficacy of therapy, reduces relapse rate and increases MST.
READ MORE HERE
